Plazomicin - Cipla
Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate; ZEMDRILatest Information Update: 16 Jun 2025
At a glance
- Originator Isis Pharmaceuticals
- Developer Cipla USA
- Class Aminoglycosides; Antibacterials; Small molecules; Urinary anti-infective agents
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pyelonephritis; Urinary tract infections
- Preregistration Bacteraemia; Nosocomial pneumonia
- No development reported Gram-negative infections; Renal failure; Respiratory tract infections; Tularaemia; Yersinia infections